TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21246795
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract capsules (equiv. 17,000 mg of fresh fruit) taken twice a day, 4 days before and 5 days after surgery
Study: 15058118
Drug: Prepared morphine
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared morphine solution 10 mg (Group Ten)
Study: 15058118
Drug: Prepared morphine
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared morphine solution 5 mg (Group Five)
Study: 15058118
Drug: Prepared morphine
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared morphine solution (Group Ten and Group Five)
Study: 11464349
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine (0.166%, 2 to 8 mL/h) and diamorphine (0.2 to 0.8 mg/h) for 24 hours before and during operation (14 patients)
Study: 11464349
Drug: Intraoperative perineural
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative perineural catheter infusing bupivacaine (0.25%, 10 mL/h) (16 patients)
Study: 7993161
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (verbal instructions and handout about medication)
Study: 2910050
Drug: Intravenous indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous indomethacin, 0.2 mg/kg per dose, three doses on the fourth day of life
Study: 790351
Drug: Betahistine hydrochloride
Normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine hydrochloride 32 mg daily for 16 weeks
Study: 28616796
Drug: Bilateral topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral topical anesthetic eye drops (Group 2)
Study: 28616796
Drug: Ipsilateral topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsilateral topical anesthetic eye drops (Group 1)
Study: 28610898
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) within 5 days of delivery
Study: 28610898
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) at 6 weeks postpartum
Study: 28610898
Drug: Immediate insertion
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate insertion of levonorgestrel contraceptive implants
Study: 21679246
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 250, 500, 1000, 1250 or 1500 mg of mildronate capsules
Study: 21679246
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of 500 mg of mildronate capsules three times a day for 13 days
Study: 17172616
Drug: Cumulative levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative levodopa dose
Study: 17172616
Drug: Cumulative levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative levodopa equivalent dose (levodopa plus pramipexole)
Study: 17172616
Drug: Cumulative levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative levodopa equivalent dose
Study: 14743580
Drug: Cholesterol-enriched lipid
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-enriched lipid emulsion (4 g/l free cholesterol)
Study: 11070454
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 microg) dry-powder inhalation
Study: 1349492
Drug: abanoquil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abanoquil 0.25 mg
Study: 1349492
Drug: abanoquil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: abanoquil 0.5 mg
Study: 1349492
Drug: abanoquil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: abanoquil 1 mg
Study: 30956216
Drug: Amiodarone prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone prophylaxis (150 mg IV bolus, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours)
Study: 30015649
Drug: Couple-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based interventions addressing traditional cardiovascular risk factors; details on dosage and duration not available.
Study: 30015649
Drug: Attachment-based interventions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based interventions, such as the Healing Hearts Together program; details on dosage and duration not available.
Study: 30015649
Drug: Couple-based interventions;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based interventions; details on dosage and duration not available.
Study: 22574587
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (AD) 10 mg, once daily, combined with Baihua Xianglian Detoxification Recipe (BXDR) twice daily
Study: 21240151
Drug: Quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine IR 800 mg/day
Study: 12600115
Drug: Intravenous reduced
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous reduced glutathione (GSH) at a dose of 1200 mg twice a week for 12 weeks
Study: 12600115
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 3000U twice a week for 12 weeks
Study: 7981015
Drug: Vinpocetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine (10 mg three times daily)
Study: 7981015
Drug: Oxazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (10 mg three times daily)
Study: 2597598
Drug: Inderex (bendrofluazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderex (bendrofluazide 5 mg and Inderal LA 160 mg)
Study: 2597598
Drug: Inderal LA
Normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inderal LA (160 mg)
Study: 6134137
Drug: Bendrofluazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (5 mg)
Study: 30796762
Drug: Phytogenic plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytogenic plant diets (various treatments)
Study: 29805491
Drug: Intravenous corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticosteroid treatment (methylprednisolone)
Study: 29805491
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid treatment (budesonide)
Study: 27139820
Drug: Cabozantinib tablet
Normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablet formulation (140 mg)
Study: 27139820
Drug: Cabozantinib tablet
Normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablet strengths (20, 40, and 60 mg)
Study: 12040355
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (1/2 NS)
Study: 12040355
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (1/2 NS) in patients with diabetes
Study: 8625180
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of postoperative COPAC chemotherapy followed by similar radiotherapy schedule (chemotherapy/radiotherapy group)
Study: 6797085
Drug: Aerosol agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol agents (specific agents not detailed)
Study: 6797085
Drug: Parasympathetic system
Normalized name: Bos taurus parasympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasympathetic system blocker
Study: 27989690
Drug: Tadalafil (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (40mg daily for six weeks)
Study: 22586334
Drug: Smoked cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis (once daily for three days)
Study: 22586334
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo cigarettes (once daily for three days)
Study: 20853602
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside in high doses (first and second course)
Study: 20853602
Drug: Aggressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive therapy
Study: 20853602
Drug: Current AML
Normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current AML treatment programs
Study: 17984737
Drug: Aminophylline (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (375 mg infusion)
Study: 15338100
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with diazepam
Study: 2091337
Drug: Artemisinine suppositories
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinine suppositories
Study: 2091337
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine
Study: 27662551
Drug: Oral pentavalent
Normalized name: rotavirus vacc, live oral pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentavalent rotavirus vaccine (RV5)
Study: 23323672
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRI) added to supportive care
Study: 17550491
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg vaginal misoprostol every six hours up to four doses
Study: 17550491
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg vaginal misoprostol every six hours up to four doses
Study: 10781464
Drug: Sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 microg combined with midazolam 1 mg
Study: 1550481
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate 90 minutes before surgery plus intraoperative neural blockade, with a postoperative analgesic regimen with combined bupivacaine hydrochloride‐morphine and indomethacin sodium (group 2)
Study: 1550481
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative pain treatment with morphine chloride and acetaminophen (group 1)
Study: 2863443
Drug: Elective testicular
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective testicular biopsy during chemotherapy
Study: 2863443
Drug: End-of-therapy testicular
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-therapy testicular biopsy
Study: 27296243
Drug: Conversation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversation Therapy (CT)
Study: 27296243
Drug: Stimulation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation Therapy (ST)
Study: 23688830
Drug: Clinician-guided Internet-delivered
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided Internet-delivered cognitive behaviour therapy (iCBT) program (the Pain Course) consisting of 5 lessons, homework tasks, additional resources, and weekly contact from a Clinical Psychologist.
Study: 10023151
Drug: Polarizing mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polarizing mixture (potassium + insulin + glucose)
Study: 8453222
Drug: Hypotonic ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic ORS solution (224 mosmol/l)
Study: 8453222
Drug: Isotonic ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic ORS solution (304 mosmol/l)
Study: 3020732
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (MaxEPA) 15 gm per day
Study: 31689510
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with mechanical debridement (MD) (Group-A)
Study: 31689510
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (AB) with mechanical debridement (MD) (Group-B)
Study: 30301642
Drug: Pre-vaccine Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-vaccine Exercise (15-minutes upper body exercise)
Study: 30301642
Drug: Pre-vaccine Arm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-vaccine Arm, Pre-vaccine Leg, Post-vaccine Arm (15-minutes of arm or leg exercises)
Study: 26510574
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy administered to the dorsum of the tongue
Study: 26510574
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a tongue scraper
Study: 26510574
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a tongue scraper combined with photodynamic therapy
Study: 21564154
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus usual treatment
Study: 21335296
Drug: Community pharmacy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacy-based falls-prevention program (medication consultation)
Study: 21335296
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication consultation)
Study: 10321505
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of leuprolide acetate every month
Study: 10321505
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg of leuprolide acetate every 3 months
Study: 23943256
Drug: Conventional restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional restorative treatment (CRT) using amalgam
Study: 23943256
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using high-viscosity glass ionomer
Study: 23943256
Drug: Ultraconservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraconservative treatment (UCT) protocol
Study: 15220164
Drug: CSL 30
Normalized name: CSL-689
DrugBank: CSL-689 (DB17726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL 30 ml kg(-1)
Study: 31504139
Drug: Ado-trastuzumab emtansine
Normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ado-trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 3 weeks until toxicity or disease progression
Study: 28454060
Drug: Conventional O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional O2 therapy (control)
Study: 26409117
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR, 1800 mg)
Study: 21572124
Drug: sialyl-TN (STn)
Normalized name: sialyl Lewis A
Approvals — FDA: no, EMA: no, PMDA: no
Description: sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine
Study: 21572124
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg KLH plus adjuvant (control group)
Study: 1616214
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg, twice daily for 5 days
Study: 6232402
Drug: 10-micrograms dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-micrograms dose of HBsAg vaccine administered at 0, 1, and 6 months
Study: 6232402
Drug: 10-micrograms dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-micrograms dose of HBsAg vaccine
Study: 29455305
Drug: Active LASER
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active LASER (904 nm, 60 mW, 250 Hz, 3.6 J per diode, total dose of 129.6 J)
Study: 27578220
Drug: Adjunctive metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive metformin therapy (in addition to insulin)
Study: 23928867
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (control group)
Study: 27578220
Drug: Adjunctive metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive metformin therapy
Study: 20696421
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment program
Study: 10790249
Drug: Treatment music
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment music tape (TT)
Study: 8864317
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg single oral dose after stopping SASP for 2 weeks
Study: 8864317
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg weekly + 2000 mg SASP daily
Study: 20087340
Drug: Drugs (888
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs (888 drugs connected to side effects)
Study: 20087340
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (199 drugs)
Study: 18593998
Drug: BMS-275183 administered
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-275183 administered under fasting conditions (A)
Study: 18593998
Drug: BMS-275183 administered
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-275183 administered after a low-fat meal (B)
Study: 18593998
Drug: BMS-275183 administered
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-275183 administered after a high-fat meal (C)
Study: 18593998
Drug: BMS-275183 administered
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-275183 administered with BSA-normalized dosing (D)
Study: 12521503
Drug: Prostin gel
Normalized name: Prostin VR
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostin gel (instant release prostaglandin gel)
Study: 9673744
Drug: Nebulised terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised terbutaline (cumulative dose 10 mg)
Study: 2562913
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac and activated charcoal
Study: 30861998
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care + conventional physical therapy
Study: 30106636
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab and an aromatase inhibitor (AI)
Study: 27401244
Drug: Tivozanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib plus mFOLFOX6 (1.5 mg orally once daily for 21 days)
Study: 27401244
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus mFOLFOX6 (5 mg/kg intravenously every 2 weeks)
Study: 23909813
Drug: Sorbitol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (10 g)
Study: 23909813
Drug: Mannitol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (10 g)
Study: 19579757
Drug: Total transfused
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total transfused blood volume greater than 30 mL over 30 days
Study: 17210036
Drug: Adenosine A(2A)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine A(2A) receptor agonist/adenosine A(3) receptor antagonist (50 micro g), administered twice daily for 7 days
Study: 17210036
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone proprionate nasal spray (FPANS), administered twice daily for 7 days
Study: 9413755
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (sterile urine group)
Study: 9413755
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (urinary tract infection group)
Study: 31489650
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg PTX in 3 divided doses plus 25 mg captopril 3 times a day
Study: 31489650
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg captopril in 3 divided doses
Study: 30359047
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response (IVR) system for daily monitoring of illicit opioid use
Study: 28723843
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate (CHO) manipulation (414 ± 2.4 g)
Study: 28723843
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate (CHO) manipulation (79.5 ± 1.0 g)
Study: 29239242
Drug: Fluconazole-loaded solid
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole-loaded solid lipid nanoparticles (FLZ-SLNs) topical gel
Study: 29239242
Drug: Candistan® 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candistan® 1% cream (control)
Study: 22784254
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment in Graves' disease patients